LATE-BREAKING CLINICAL TRIAL
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary InterventionResults of the ARMYDA-ACS Randomized Trial
Giuseppe Patti, MD, FACC*,
Vincenzo Pasceri, MD, PhD, FACC ,
Giuseppe Colonna, MD ,
Marco Miglionico, MD*,
Dionigi Fischetti, MD ,
Gennaro Sardella, MD, FACC ,
Antonio Montinaro, MD and
Germano Di Sciascio, MD, FACC, FESC*,*
* Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy
Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
Interventional Cardiology Unit, Vito Fazzi Hospital, Lecce, Italy
Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.
Manuscript received February 10, 2007;
revised manuscript received February 23, 2007,
accepted February 23, 2007.
* Reprint requests and correspondence: Dr. Germano Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico University, Via E. Longoni 83, 00155 Rome, Italy. (Email: g.disciascio{at}unicampus.it).
Objectives: This study sought to investigate potential protective effects of atorvastatin in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI).
Background: Randomized studies have shown that pretreatment with atorvastatin may reduce periprocedural myocardial infarction in patients with stable angina during elective PCI; however, this therapy has not been tested in patients with ACS.
Methods: A total of 171 patients with nonST-segment elevation ACS were randomized to pretreatment with atorvastatin (80 mg 12 h before PCI, with a further 40-mg preprocedure dose [n = 86]) or placebo (n = 85). All patients were given a clopidogrel 600-mg loading dose. All patients received long-term atorvastatin treatment thereafter (40 mg/day). The main end point of the trial was a 30-day incidence of major adverse cardiac events (death, myocardial infarction, or unplanned revascularization).
Results: The primary end point occurred in 5% of patients in the atorvastatin arm and in 17% of those in the placebo arm (p = 0.01); this difference was mostly driven by reduction of myocardial infarction incidence (5% vs. 15%; p = 0.04). Postprocedural elevation of creatine kinase-MB and troponin-I was also significantly lower in the atorvastatin group (7% vs. 27%, p = 0.001 and 41% vs. 58%, p = 0.039, respectively). At multivariable analysis, pretreatment with atorvastatin conferred an 88% risk reduction of 30-day major adverse cardiac events (odds ratio 0.12, 95% confidence interval 0.05 to 0.50; p = 0.004).
Conclusions: The ARMYDA-ACS trial indicates that even short-term pretreatment with atorvastatin may improve outcomes in patients with ACS undergoing early invasive strategy. These findings may support routine use of high-dose statins before intervention in patients with ACS.
|
Abbreviations and Acronyms
| | CRP = C-reactive protein | | MACE = major adverse cardiac event | | PCI = percutaneous coronary intervention |
|
This article has been cited by other articles:

|
 |

|
 |
 
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1128 - 1133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Abbate, M. C. Kontos, and G. G.L. Biondi-Zoccai
No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction
Eur. Heart J.,
August 1, 2008;
29(15):
1795 - 1797.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Kereiakes, M. A. Turco, J. Breall, N. Z. Farhat, R. L. Feldman, B. McLaurin, J. J. Popma, L. Mauri, P. Zimetbaum, J. Massaro, et al.
A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions: Results of the AMEthyst Randomized Controlled Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nusca, R. Melfi, and G. Di Sciascio
Review: Percutaneous coronary interventions and statins therapy
Therapeutic Advances in Cardiovascular Disease,
April 1, 2008;
2(2):
101 - 107.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D.C. Suh, J.K. Kim, J.W. Choi, B.S. Choi, H.W. Pyun, Y.J. Choi, M.-H. Kim, H.R. Yang, H.I. Ha, S.J. Kim, et al.
Intracranial Stenting of Severe Symptomatic Intracranial Stenosis: Results of 100 Consecutive Patients
AJNR Am. J. Neuroradiol.,
April 1, 2008;
29(4):
781 - 785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nahrendorf, D. Sosnovik, J. W. Chen, P. Panizzi, J.-L. Figueiredo, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder
Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury
Circulation,
March 4, 2008;
117(9):
1153 - 1160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano and E. Braunwald
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1386 - 1395.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. D Cahoon Jr and M. A Crouch
Preprocedural Statin Therapy in Percutaneous Coronary Intervention
Ann. Pharmacother.,
October 1, 2007;
41(10):
1687 - 1693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Yellon and D. J. Hausenloy
Myocardial Reperfusion Injury
N. Engl. J. Med.,
September 13, 2007;
357(11):
1121 - 1135.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Atorvastatin Before PCI Benefits ACS Patients
Journal Watch Cardiology,
May 9, 2007;
2007(509):
4 - 4.
[Full Text]
|
 |
|

|
 |

|
 |
 
A. S Wierzbicki
Voodoo medicine -- cardiovascular trials jinxed in New Orleans: Dr Anthony Wierzbicki discusses highlights of the 56th Annual Scientific Session of American College of Cardiology held at Morial Conventions Centre in New Orleans March 24th--27th, 2007
The British Journal of Diabetes & Vascular Disease,
May 1, 2007;
7(3):
142 - 144.
[PDF]
|
 |
|
|